VRAX

Virax Biolabs Group Ltd VRAX

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$12.4K

Quarter to Mar 31

Net income

$-5.02M

Quarter to Mar 31

Free cash flow

$-4.88M

Quarter to Mar 31

Top Institutional Holders

as of Q2 2026
$77.6K total
JANE STREET GROUP, LLC
$77.6KNew
UBS Group AG
$12New
See all 2 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

FY 2026
EDGAR

Net Income

FY 2026
EDGAR

EPS (Diluted)

FY 2026
EDGAR

ROIC

FY 2026
EDGAR

Free Cash Flow

FY 2026
EDGAR

Loading ratio trend…

VRAX key financials by period

Reported revenue, net income and operating margin by fiscal year, from Virax Biolabs Group Ltd's annual filings on SEC EDGAR.

Virax Biolabs Group Ltd reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2026$12.4K$-5.0M—
FY 2025$6.3K$-6.1M—
FY 2024$156.4K$-6.7M—
FY 2023$8.6K$-5.5M—
FY 2021$123.8K$-651.0K—
Source: VRAX filings on SEC EDGAR →

About Virax Biolabs Group Ltd (VRAX): stock profile, AI score and financials

Virax Biolabs Group Ltd (VRAX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. VRAX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (FY 2026), Virax Biolabs Group Ltd reports quarterly revenue of $12.4K, net income of $-5.0M, free cash flow of $-4.9M. VRAX trades on the Nasdaq exchange and files with the SEC under CIK 1885827. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VRAX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Virax Biolabs Group Ltd directly from SEC EDGAR.

SEC EDGAR: CIK 1885827 →